NASDAQ:MBRX Moleculin Biotech Q3 2025 Earnings Report $0.42 +0.03 (+6.25%) Closing price 04:00 PM EasternExtended Trading$0.41 -0.02 (-4.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Moleculin Biotech EPS ResultsActual EPS-$0.13Consensus EPS -$0.20Beat/MissBeat by +$0.07One Year Ago EPSN/AMoleculin Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoleculin Biotech Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time7:00AM ETUpcoming EarningsMoleculin Biotech's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Moleculin Biotech Earnings HeadlinesMoleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public OfferingJuly 31 at 6:54 PM | finanznachrichten.deMoleculin Biotech stock is sinking Friday: What's going on?July 31 at 6:54 PM | msn.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.August 3 at 1:00 AM | Base Camp Trading (Ad)Moleculin Biotech Prices $9.3 Million Best-Efforts Public Offering with WarrantsJuly 31 at 10:30 AM | quiverquant.comQMoleculin Announces Pricing of $9.3 Million Public OfferingJuly 31 at 10:12 AM | globenewswire.comMoleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed PatientsJuly 31 at 8:52 AM | finance.yahoo.comSee More Moleculin Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email. Email Address About Moleculin BiotechMoleculin Biotech (NASDAQ:MBRX) is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need. The company’s pipeline includes multiple product candidates at various stages of development. WP1066 is an immunotherapeutic compound designed to inhibit the STAT3 signaling pathway, which is implicated in the growth and survival of certain brain tumors and other malignancies. Annamycin is an anthracycline derivative engineered to overcome resistance mechanisms in acute myeloid leukemia (AML) with the goal of improving safety and efficacy. In addition, Moleculin is advancing WP1220, a broad-spectrum antiviral candidate targeting poxviruses and coronaviruses through inhibition of viral replication. Headquartered in Houston, Texas, Moleculin Biotech collaborates with academic institutions and contract research organizations to conduct its preclinical and clinical studies. The company’s development programs include Phase 1 and Phase 2 clinical trials in the United States, with plans to initiate additional studies in international markets as regulatory approvals are secured. Such partnerships and trial sites enable Moleculin to advance its candidates efficiently through the clinical development pathway. Founded in 2012, Moleculin Biotech is led by Walter Klemp, President and Chief Executive Officer, a veteran in the biotech industry with experience in drug development and corporate strategy. Under his leadership, the company continues to expand its research capabilities and global trial network, aiming to bring its innovative therapies to patients with critical oncological and viral diseases.View Moleculin Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have ControlStrategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31A Sweet Beat and a Wearables Rally Came With Reasons to PauseChevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAbbVie Quietly Solved Its Biggest Problem—Now What?Netflix's Big Sell-Off May Be Sending the Wrong Signal Upcoming Earnings Spotify Technology (8/4/2026)SpaceX (8/4/2026)Electronic Arts (8/4/2026)McDonald's (8/4/2026)Toyota Motor (8/4/2026)Coca-Cola Europacific Partners (8/4/2026)BP (8/4/2026)EOG Resources (8/4/2026)Energy Transfer (8/4/2026)Marathon Petroleum (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
